They developed a new surface coating for medical devices using materials already approved by the Food and Drug Administration (FDA.
so drugs targeting STAT3 could be used in cancer therapy. However STAT3 is also important in the development of the immune system.
Stunningly the two that worked were the older drugs he had been given at the clinic. I can only assume that
Three weeks later I was asked to join a nonprofit organization working on new models for drug development called the Institute for Life sciences Collaboration Kinch said.
'Antibiotics are crashingin his last position as managing director of the Center for Molecular Discovery at Yale university Kinch had assembled a huge database of information about drug discovery and development in the pharmaceutical industry.
In an article in Drug Discovery Today Kinch summarized the financial constraints that have led to the current crisis in antibiotic supply.
or because they've been replaced by new versions of the same drug. Introductions are declining
which is now dominated by small companies such as Cubist Pharmaceuticals formed in 1992 specifically to focus on drugs for resistant bacterial infections that could have higher price points.
because some of the new drugs are not general-purpose antibiotics. They include for example an acne medication
A patent gives a company 20 years of protection for a new drug but it takes 11 years of clinical trial experience on average to get a drug approved.
That means the typical company has nine years under patent to earn back the development costs before a generic comes in.
If the drug is an antibiotic there is an additional catch. Because of rising resistance doctors hold new antibiotics in reserve using them only in cases of dire need.
which has long been used as a drug of last resort. When you hold a drug in reserve Kinch said you're eating into the patent time a company has to recoup its development costs.
If you've got this vancomycin-like situation where the drug is sitting on a shelf--quite literally sitting on a shelf--how is a company going to make its money back?
It can't price the drug at $10000 a dose. Companies have decided consistently there is no exit from this trapas long as we hold to the current model for drug development.
What to do about it? In the U s. we're used to turning to the NIH to solve problems like this
but the NIH budget which doubled in 2009 has fallen continuously ever since. It is now 30 percent below 2009 levels in constant dollars.
or more be offered for the development of new drugs which would then be sold for modest prices by other companies.
Antibiotics are not the only drug class heading for trouble--Kinch mentions that HIV/AIDS drugs are following a similar trajectory
--but they have become the poster child for the larger problem of drug discovery and development in part because they underpin every part of modern medical practice from surgery to cancer treatment and pretty much everything in between.
and opened the door for drug discovery and transplantation therapy in diabetes, "Fuchs said. And Jose Oberholtzer, M d.,Associate professor of Surgery, Endocrinology and Diabetes,
the study offers a blueprint for development of a drug specific to the task k
Kilmer and co-author Jesse Sussell examined one-year rearrest rates among those arrested for eligible offenses--such as theft, vandalism, drug offenses, assault and disorderly conduct--inside and outside the catchment area both before and after the Community Justice Center opened.
which we now plan to use to screen the impact of drugs and antibodies that can shut it down,
The novelty of this formulation lies in the combination of the two drugs. Previous clinical trials have evaluated the efficacy, safety and tolerability of CIP on human patients.
Dry powder inhalers exhibit several advantages over traditional drug delivery methods, including improved formulation stability, enhanced delivery efficiency, excellent portability and ease of use.
And many drugs work by targeting specific membrane proteins.""Currently, scientists only know the structure of a small handful of membrane proteins.
Our research paves the way to understand the structure of the thousands of different types of membrane proteins to allow the development of many new drugs
#Universal Ebola drug target identified by researchers University of Utah biochemists have reported a new drug discovery tool against the Ebola virus.
This new tool can be used as a drug target in the discovery of anti-Ebola agents that are effective against all known strains and likely future strains.
and is currently screening for drugs against the target.)The Utah scientists designed peptide mimics of a highly conserved region in the Ebola protein that controls entry of the virus into the human host cell,
Importantly, the researchers were able to demonstrate this peptide target is suitable for use in high-throughput drug screens.
These kinds of screens allow rapid identification of potential new drugs from billions of possible candidates.
Current experimental drugs generally target only one of Ebola's five species."The current growing epidemic demonstrates the need for effective broad-range Ebola virus therapies,
Therefore, our target will enable the discovery of drugs with the potential to treat any future epidemic,
but a number of promising experimental drugs are being advanced aggressively to clinical trials to address the current crisis. Dr. Eckert notes,"
which are promising drug candidates. Unlike natural peptides, they are digested not by enzymes in the blood.
and may be key to developing new drugs and therapies. Specifically principal investigator Albert R. La Spada MD Phd professor of cellular and molecular medicine chief of the Division of Genetics in the Department of Pediatrics and associate director of the Institute for Genomic
because not only have shown we this particular part of the protein is essential for necroptosis we also have a starting point in a drug discovery program.
Dr Murphy said institute scientists would now embark on a collaborative project with Catalyst Therapeutics to develop a potent new drug based on the small molecule identified in the study.
The optimal drug therapies we have today often aren't enough to manage this disease for some patients
Drug and device therapies that are currently available for heart failure improve that same quality of life score by only five or 10 points.
"Hijacking the hijacker"A tempting premise is to use this same machinery to introduce drugs or genes into the nervous system,"Dr. Perlson added.
and limit the spread of the virus. A drug of this type affects the physical properties of the virus's DNA
which means that the drug can resist the virus's mutations said Alex Evilevitch. The second study that Evilevitch and his colleagues have published recently is about bacteriophages
and demonstrated how the MFICS can size droplets precisely a useful function for drug delivery or studying microreactor chambers.
and only one therapy has been approved by the Food and Drug Administration. While most of these vaccines are created with dendritic cells,
In 2014, Cowan identified two drugs with the potential to convert stem cells that make white fat into those that would make brown. his latest study gives us new tools and targets to use in the battle against obesity
-or right-handed form may have a multitude of practical applications, potentially leading to new and improved drugs, diagnosis methods, and pesticides.
The breakthrough could be important in developing effective molecules for use in a wide range of industries everything from the development of safer new drugs and disease diagnosis to less toxic pesticides.
for instance with chiral drugs. Presently, more than 50 per cent of all drugs produced are active in only one of their two handed forms.
The chemistry of life Dr Ivan Powis, Professor of Chemical Physics in the University School of Chemistry, who led the research,
for instance the well-known malformation of the limbs of infants of pregnant women taking the Thalidomide drug to relieve morning sickness that occurred around 1960.
In addition to the development of effective new drugs and diagnosis methods for diseases including cancer, it could potentially lead to new reenpesticides using pheromones tailored specifically to attract pollinators
or even stop their current HIV drug regimen and clear the virus from the body altogether,
Certain drugs help suppress the virus, but since the human immune system can clear the virus from the body,
people with HIV have the virus for life. espite increased scientific understanding of HIV and better prevention and treatment with available drugs, a majority of the 35 million people living with HIV,
#Yale Researchers Successfully Treat Eczema with Rheumatoid arthritis Drug A team of scientists at Yale university used a rheumatoid arthritis drug to successfully treated patients with moderate to severe eczema.
The same rheumatoid arthritis drug (tofacitinib citrate) has shown recently to reverse two other disfiguring skin conditions, vitiligo and alopecia areata.
Based on current scientific models of eczema biology, assistant professor of dermatology Dr. Brett King. hypothesized that a drug approved for rheumatoid arthritis,
In the new study, King and his colleagues report that treatment with the drug led to dramatic improvement in six patients with moderate to severe eczema who had tried previously conventional therapies without success. During treatment all six
They initially sought to develop nanoparticles that could be used to deliver drugs to cancer cells. Brandl had synthesized previously polymers that could be cleaved apart by exposure to UV LIGHT.
But he and Bertrand came to question their suitability for drug delivery, since UV LIGHT can be damaging to tissue and cells,
and approved by the Food and Drug Administration as a food additive, and polylactic acid, a biodegradable plastic used in compostable cups and glassware.
The study also suggests the broader potential for adapting nanoscale drug-delivery techniques developed for use in environmental remediation. hat we can apply some of the highly sophisticated,
and other disciplines also tested the response of tumor cells with specific mutations to anticancer drugs.
in addition to loss of NF1, multiple factors need to be tested to predict the response to the drugs. t opens the door to more research,
Clinics have to track their drugs, generate tedious reports to get new supplies and deliver those reports to central facilities.
the clinic wouldn get the drugs it needed to treat its patients. The 3g technology has allowed clinics to computerize much of their administrative work,
All of these drugs are being developed under the FDA nimal rule, which requires extensive efficacy data in animal models,
Since many of these drugs have passed already human safety testing they could be on the market before the next nuclear catastrophe strikes p
its Scanaflow device is an at home urine-testing apparatus that can test for drugs or even a possible pregnancy. lot more healthcare is going to happen in the home in the future,
a first that could allow researchers to test drugs on working muscle without damaging a live host.
and responds to drugs just like regular human muscle as replacements for lost musculature, which suggests the samples are still too small to be useful.
and it looks like it will be a real boon for researchers trying to figure out the effects of various diseases and drugs on the body.
Worried that your local pharmacy is slipping you some sort of generic drug instead of the real thing?
and drugs they eat. Using near infrared spectroscopy the device connects with a mobile app
The Regulatory Pathwaythe U s. Food & Drug Administration (FDA) has created three categories of MMAS: Of more than 43000 health-related apps available by 2013 only 103 were regulated FDA Tighe says.
The Regulatory Pathwaythe U s. Food & Drug Administration (FDA) has created three categories of MMAS: Of more than 43000 health-related apps available by 2013 only 103 were regulated FDA Tighe says.
That because just a month earlier, in November 2013, the Food and Drug Administration had cracked down on 23andme.
or take a drug overdose. Critics of the decision said it had more to do with questions about
or lower, their risk for drug reactions, common diseases, or personality traits such as a lack of empathy.
and avoid drugs like Novocain. think that how people should be using thiss a conversation-starter with medical professionals,
#Gene-Silencing Drugs Finally Show Promise The disease starts with a feeling of increased clumsiness.
because it suggested a way to shut down the production of any protein in the body including those connected with diseases that couldn't be touched with ordinary drugs.
Never mind that no one knew how to make a drug that could trigger RNAI. In fact that challenge would bedevil the researchers for the better part of a decade.
But now Alnylam is testing a drug to treat FAP in advanced human trials. It s the last hurdle before the company will seek regulatory approval to put the drug on the market.
Although it s too early to tell how well the drug will alleviate symptoms it s doing
what the researchers hoped it would: it can decrease the production of the protein that causes FAP by more than 80 percent.
Alnylam has more than 11 drugs including ones for hemophilia Hepatitis b and even high cholesterol in its development pipeline and has three in human trials progress that led the pharmaceutical company Sanofi to make a $700 million investment in the company last winter.
All told there are about 15 RNAI-based drugs in clinical trials from several research groups and companies.
The early mechanisms were too toxic at the doses required to be used as drugs. As a result delivering RNA through the bloodstream like a conventional drug seemed a far-off prospect.
The company tried a shortcut of injecting chemically modified RNA directly into diseased tissue for example into the retina to treat eye diseases.
because it didn t perform as well as up-and-coming drugs from other companies. By 2010 some of the major drug companies that were working with and investing in Alnylam lost patience.
Better nanoparticles improved the potency of a drug a hundredfold and its safety by about five times clearing the way for clinical trials for FAP a crucial event that kept the company alive.
This approach allows for the drug to be administered with a simple injection that patients could give themselves at home.
In addition to being easier to administer the new sugar-based drugs are potentially cheaper to make.
For all of their benefits the drug delivery mechanisms Alnylam uses have one flaw they re effective only for delivering drugs to liver cells.
but if it maintains its momentum the drugs currently in clinical trials could represent just a small portion of the benefits of the discovery of RNAI i
And while wee still far from turning new insights into effective and safe drugs at least the emerging knowledge is giving researchers some options in exploring potential treatments.
drug researchers might be able to zero in on specific common pathways or types of cells in attempts to tackle these disorders.
and laboratories to detect patterns that might alert doctors to potential adverse drug interactions and other prescription issues.
the U s. Food & Drug Administration approved Neuropace, the first implant that both records from the brain and stimulates it (see apping Seizures Away.
and who can be helped with drugs and psychotherapy. his is never going to be a first-line option:
Researchers have speculated for decades that a drug that could inhibit IDE might help some type 2 diabetes patients.
Small-molecule drugs, which make up the majority of medicines, are compounds far smaller than less common biological medicines like antibodies.
which may be why the Harvard team was able to identify an IDE-controlling drug when so many had failed in the past.
The newly identified IDE inhibitor could be the starting point for developing a powerful new drug for type 2 diabetes.
#Nerve-Stimulating Implant Could Lower Blood pressure An implantable device that reduces blood pressure by stimulating a nerve in the neck could someday be an alternative to drugs for controlling hypertension.
and some patients taking the drugs suffer from side effects including fatigue and lightheadedness. An implantable device would allow reducing the blood pressure in these patients
and some find that side effects make the drug regimens difficult to maintain. The worst part is that the blood pressure is still high
Whereas drugs cannot adapt to patient activities an intelligent implant can he says which could offer a way to treat hypertension on demand d
The methods developed to create the designer genomic structure could help synthetic biologists better use the single-celled fungi as biological factories for chemicals like biofuels and drugs.
or perhaps be better factories for useful molecules like fuels and drugs. Already the researchers have shown that inducing mutation in yeast using the designer sites led to some cells that grow more slowly,
animal efficacy models are often predictive of a drug effects in humans, said Gerard Wright, director of the Institute for Infectious disease Research at Mcmaster University in Hamilton, Canada,
but also expedite the drug development process, "Dr Mandal said. Dr Kameshwar Prasad, professor and head of neurology at AIIMS, said the findings are preliminary."
Early identification can help in giving drug therapy to slow the degeneration process and develop strategies to enhance the patient's living environment,
Several recently developed drugs--bevacizumab, ranibizumab and aflibercept--can help treat these blood vessels by blocking the action of VEGF,
But studies have shown that although these drugs slow progression to proliferative diabetic retinopathy, it does not reliably prevent it,
Sodhi suggested if a drug can be found that safely blocks the second protein's action in patients'eyes
Several recently developed drugs--bevacizumab, ranibizumab and aflibercept--can help treat these blood vessels by blocking the action of VEGF,
But studies have shown that although these drugs slow progression to proliferative diabetic retinopathy, it does not reliably prevent it,
Sodhi suggested if a drug can be found that safely blocks the second protein's action in patients'eyes
Using the invention on carboplatin a common cancer treatment drug, used against ovarian and lung cancers has boosted the potency by almost five times.
"The tool can be used to take away the wastage in a drug, meaning that you need less of it to do the same work.
and could mean that the drugs treat tumours much more effectively. As well as helping with treatment, the tool could cut down the wastage created during the process of making drugs.
That could make the pharmaceutical much more sustainable and reduce their impact on the environment.
Using the invention on carboplatin a common cancer treatment drug, used against ovarian and lung cancers has boosted the potency by almost five times.
"The tool can be used to take away the wastage in a drug, meaning that you need less of it to do the same work.
and could mean that the drugs treat tumours much more effectively. As well as helping with treatment, the tool could cut down the wastage created during the process of making drugs.
That could make the pharmaceutical much more sustainable and reduce their impact on the environment.
have been developed into successful drugs. It is hoped that T-VEC could be used in combination with these.
have already been submitted to drugs regulators in Europe and the USA. Viral immunotherapies are also being investigated for use against advanced head and neck cancers, bladder cancers and liver cancers.
have been developed into successful drugs. It is hoped that T-VEC could be used in combination with these.
have already been submitted to drugs regulators in Europe and the USA. Viral immunotherapies are also being investigated for use against advanced head and neck cancers, bladder cancers and liver cancers.
This is an important step for the future production of large numbers of these cells for use in cell transplantation therapies or large-scale drug screens, researchers from the Molecular Medicine Institute in Lisbon,
Researchers have engineered successfully E coli bacteria to produce new forms of antibiotics including three that show promise in fighting drug-resistant bacteria.
harnessing E coli to synthesise dozens of new forms of the drug that have a slightly different structure from existing versions.
but also developed a platform for using E coli to produce the drug, "he said. Over the past 11 years, Pfeifer's research has focused on manipulating E coli
so that the drug they make is slightly different than versions used in hospitals today. The process of creating erythromycin begins with three basic building blocks called metabolic precursors chemical compounds that are combined
Researchers have engineered successfully E coli bacteria to produce new forms of antibiotics including three that show promise in fighting drug-resistant bacteria.
harnessing E coli to synthesise dozens of new forms of the drug that have a slightly different structure from existing versions.
but also developed a platform for using E coli to produce the drug, "he said. Over the past 11 years, Pfeifer's research has focused on manipulating E coli
so that the drug they make is slightly different than versions used in hospitals today. The process of creating erythromycin begins with three basic building blocks called metabolic precursors chemical compounds that are combined
which is being called the world's first digital drug, can zap your brain to make you feel
#In a first, drug offers hope for children with dwarfism An experimental drug, vying to become the first approved treatment for dwarfism, improved growth in children by a significant amount in a preliminary study, the drug's developer,
Biomarin Pharmaceutical, said on Wednesday. In the study, the 10 children who got the highest dose of the drug grew at an average rate of 6. 1cm,
or 2. 4 inches, per year, about a 50%increase from the four centimetres per year they were growing before starting the drug.
The growth rate while on the drug was similar to that of a child without the condition
the company said. Wall street investors and analysts had been hoping for a 50%improvement in growth rate,
a drug already marketed for certain children, can also increase the growth rate for people with dwarfism to 6 centimetres per year
The drug, which is called BMN 111 or vosoritide, is aimed at treating achondroplasia, the most common form of dwarfism.
000 children with the condition in the markets in North america, Europe, Asia and Latin america in which it anticipates selling the drug.
The drug would not be expected to work in adults because they have stopped growing. Women with achondroplasia typically grow to about four feet tall,
The drug is welcomed not universally. Some people with dwarfism say it is not a disease that needs treatment.
Understanding the pathways the parasite uses means that future drugs could be designed precisely to kill the parasite but with limited toxicity
with the parasite continually working to find ways to survive our drug treatments. This study opened the door on potential new treatments that could find
The findings also provide strong evidence that certain type-2 diabetic drugs, belonging to a new class known as SGLT2 inhibitors
and Drug Administration and were launched recently in India, could potentially block glucose uptake and reduce tumour growth and increase survival among pancreatic and prostate cancer patients.
and progression to AIDS that you would expect without drug therapy, "said lead author Giovanna Rappocciolo, assistant professor at University of Pittsburgh in the US.
"These results improve understanding of how nonprogressors control HIV without drug therapy and potentially may contribute to new approaches to manage HIV infection,"Rappocciolo added.
#utated lepto bacteria resistant to drugs, heatmumbai: Scientists at the premier Regional Medical Reference Centre (RMRC) at Port Blair have found that the bacterial species that causes leptospirosis is no longer socially aloof,
and intricately patterned shapes that could ultimately lead to injectable materials for delivering drugs or cells into the human body.
Among other applications for the automated DNA folding process include helping researchers develop nanoscale structures for targeted drug delivery
including drug delivery systems, possibly in the next 5 to 10 years. i
#3d printed smartphone device reads ELISA diagnostic tests accurately and within one minute In remote or developing countries,
#CAP-XX Introduces Thinline Supercapacitors with Unique Nanotechnology Construction Examples include wearables (medical, fitness and health monitors, smart watches, drug delivery systems), portables (active
A promising area of use seems to be the transport of drugs to specific areas of the body.
This sort of'smart'container for medicines could carry out carefully planned drug therapy in a selected organ in the human body.
The project goal is to develop new tools to elucidate the mechanism of action of a threat agent, drug, biologic or chemical on living cells within 30 days from exposure.
As a result of this damage the researchers believe the drug may not deliver the desired therapeutic effect in patients
It is assumed just that the drugs are delivered into the body intact.""We have shown that silver is catalytically degrading the chemotherapy drugs,
as well as the drug's reactions with silver and graphene. XPS is used a technique to measure the surface chemistry of a particular material by firing a beam of x-rays at it
which there is a massive loss of the element fluoride from the drug, leading to the creation of HF.
and that graphene caused no damage to the drug. Graphene is a biocompatible material with low toxicity that has already been suggested as an external coating for biomedical applications.
Together with our collaborators and students, we are increasing our understanding of the critical interactions between drugs and medical coatings,
Overtext Web Module V3.0 Alpha
Copyright Semantic-Knowledge, 1994-2011